– USA, CA – Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced the appointment of current member Dr. Steve Mento (Ph.D.) as Executive Chairman and Interim President and CEO, effective immediately.
Former chairman, Dr. David Crean (Ph.D.) will continue to serve as a Board member as Lead Independent Director.
Richard Pascoe has stepped down as President and CEO and from the Board, effective immediately. A search has commenced to identify a permanent CEO.
“On behalf of the entire Board of Directors, I would like to thank Rich for his leadership throughout his tenure at Histogen. He led the company through the successful completion of its merger with Conatus Pharmaceuticals and multiple pivotal phases of growth including the initiation and continued progress of the Company’s clinical trials,” said Lead Independent Director, Dr. David Crean. “We are confident that Steve’s experience at the company and proven track record, including prior leadership of the organization will provide a seamless transition at this time.”
“I am confident that we have the innovative technology, proprietary processes along with the right strategy and team at Histogen to be a leader in restorative therapeutics. We also plan to provide additional value through the continued development of our caspase portfolio,” added Dr. Steve Mento, Executive Chairman, and Interim CEO.
About Dr. Steven J. Mento
Dr. Mento has served as a member of our Board since July 2005. Dr. Mento was one of Conatus’ co-founders and served as Conatus’ President and CEO from July 2005 until the merger. From July 2005 until December 2012, Dr. Mento also served as chairman of Conatus’ board of directors. Dr. Mento has over 35 years of combined experience in the biotechnology and pharmaceutical industries serving in a broad range of senior executive and scientific positions. He previously served as President, CEO, and a member of the Board of Directors of Idun Pharmaceuticals before its sale in 2005 to Pfizer.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell-conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications, including joint cartilage regeneration, spinal disk repair, tendon, ligament, and other soft tissue repairs.
For more information: https://histogen.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
